Published in Nature on March 01, 2009
Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol (2009) 7.89
The role of toxin A and toxin B in Clostridium difficile infection. Nature (2010) 5.32
The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev (2010) 4.48
Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol (2009) 3.66
Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun (2009) 3.36
Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature (2014) 2.82
Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol (2010) 2.32
Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol (2010) 2.29
Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev (2011) 2.22
Clinical Clostridium difficile: clonality and pathogenicity locus diversity. PLoS One (2011) 2.04
Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J Infect Dis (2013) 2.03
Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis (2011) 1.98
Rapid and sensitive loop-mediated isothermal amplification test for Clostridium difficile detection challenges cytotoxin B cell test and culture as gold standard. J Clin Microbiol (2010) 1.85
Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection. J Clin Microbiol (2009) 1.85
Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol (2010) 1.82
Cloning and variation of ground state intestinal stem cells. Nature (2015) 1.78
Precise manipulation of the Clostridium difficile chromosome reveals a lack of association between the tcdC genotype and toxin production. Appl Environ Microbiol (2012) 1.70
What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection? J Clin Microbiol (2010) 1.70
Innate Immune Defenses Mediated by Two ILC Subsets Are Critical for Protection against Acute Clostridium difficile Infection. Cell Host Microbe (2015) 1.66
Rational design of inhibitors and activity-based probes targeting Clostridium difficile virulence factor TcdB. Chem Biol (2010) 1.60
Evolutionary Trade-Offs Underlie the Multi-faceted Virulence of Staphylococcus aureus. PLoS Biol (2015) 1.55
Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS Pathog (2013) 1.55
Clostridium difficile has two parallel and essential Sec secretion systems. J Biol Chem (2011) 1.50
Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. J Clin Microbiol (2010) 1.49
Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. Nature (2016) 1.47
Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol (2012) 1.47
Structural organization of the functional domains of Clostridium difficile toxins A and B. Proc Natl Acad Sci U S A (2010) 1.44
Integration of metabolism and virulence by Clostridium difficile CodY. J Bacteriol (2010) 1.43
Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty? J Mol Diagn (2011) 1.41
Concurrent infections of Giardia duodenalis, Enterocytozoon bieneusi, and Clostridium difficile in children during a cryptosporidiosis outbreak in a pediatric hospital in China. PLoS Negl Trop Dis (2013) 1.41
Importance of Glutamate Dehydrogenase (GDH) in Clostridium difficile Colonization In Vivo. PLoS One (2016) 1.40
Spironolactone and colitis: increased mortality in rodents and in humans. Inflamm Bowel Dis (2011) 1.40
A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog (2011) 1.39
Structure-function analysis of inositol hexakisphosphate-induced autoprocessing in Clostridium difficile toxin A. J Biol Chem (2009) 1.39
The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives. Gut Microbes (2010) 1.37
Clostridium difficile Toxin B causes epithelial cell necrosis through an autoprocessing-independent mechanism. PLoS Pathog (2012) 1.34
Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens. J Clin Microbiol (2012) 1.34
Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes (2012) 1.33
Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol (2009) 1.33
Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes (2011) 1.29
The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog (2011) 1.28
Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog (2010) 1.26
Cwp84, a surface-associated cysteine protease, plays a role in the maturation of the surface layer of Clostridium difficile. J Biol Chem (2009) 1.25
Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis (2012) 1.25
Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun (2011) 1.24
A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun (2012) 1.22
Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol (2012) 1.22
Clostridium difficile toxins: mediators of inflammation. J Innate Immun (2012) 1.21
Is repeat PCR needed for diagnosis of Clostridium difficile infection? J Clin Microbiol (2010) 1.20
Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem (2011) 1.19
Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain. J Infect Dis (2010) 1.19
Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. Nat Med (2011) 1.19
Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes (2010) 1.19
Clostridium difficile infection. Am J Med Sci (2010) 1.17
Inositol hexakisphosphate-induced autoprocessing of large bacterial protein toxins. PLoS Pathog (2010) 1.17
Models for the study of Clostridium difficile infection. Gut Microbes (2012) 1.16
The relationship between phenotype, ribotype, and clinical disease in human Clostridium difficile isolates. Anaerobe (2013) 1.14
Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat Rev Gastroenterol Hepatol (2016) 1.13
Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci (2010) 1.13
The repetitive oligopeptide sequences modulate cytopathic potency but are not crucial for cellular uptake of Clostridium difficile toxin A. PLoS One (2011) 1.13
Secretion of Clostridium difficile toxins A and B requires the holin-like protein TcdE. PLoS Pathog (2012) 1.12
The Clostridium difficile cell wall protein CwpV is antigenically variable between strains, but exhibits conserved aggregation-promoting function. PLoS Pathog (2011) 1.11
Development and application of new mouse models to study the pathogenesis of Clostridium perfringens type C Enterotoxemias. Infect Immun (2009) 1.10
Proline-dependent regulation of Clostridium difficile Stickland metabolism. J Bacteriol (2012) 1.09
Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis (2012) 1.09
Clostridium difficile infection in the twenty-first century. Emerg Microbes Infect (2013) 1.09
Mutagenic analysis of the Clostridium difficile flagellar proteins, FliC and FliD, and their contribution to virulence in hamsters. Infect Immun (2011) 1.09
Infectious diarrhea: Cellular and molecular mechanisms. Gut Microbes (2010) 1.08
Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers. Nat Commun (2013) 1.08
Genetic manipulation of Clostridium difficile. Curr Protoc Microbiol (2011) 1.08
Novel molecular type of Clostridium difficile in neonatal pigs, Western Australia. Emerg Infect Dis (2013) 1.08
PrsW is required for colonization, resistance to antimicrobial peptides, and expression of extracytoplasmic function σ factors in Clostridium difficile. Infect Immun (2011) 1.08
Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog (2013) 1.08
The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07
Both, toxin A and toxin B, are important in Clostridium difficile infection. Gut Microbes (2011) 1.06
Clostridium difficile MazF toxin exhibits selective, not global, mRNA cleavage. J Bacteriol (2012) 1.06
Culturing and maintaining Clostridium difficile in an anaerobic environment. J Vis Exp (2013) 1.05
Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury. Gastroenterology (2010) 1.04
Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem (2014) 1.04
Outcomes in patients tested for Clostridium difficile toxins. Diagn Microbiol Infect Dis (2012) 1.03
Comparison of real-time PCR techniques to cytotoxigenic culture methods for diagnosing Clostridium difficile infection. J Clin Microbiol (2010) 1.03
TcdC does not significantly repress toxin expression in Clostridium difficile 630ΔErm. PLoS One (2012) 1.02
Clostridium difficile toxin B-induced necrosis is mediated by the host epithelial cell NADPH oxidase complex. Proc Natl Acad Sci U S A (2013) 1.02
Neutralization of Clostridium difficile toxin A using antibody combinations. MAbs (2011) 1.01
Structural basis for substrate recognition in the enzymatic component of ADP-ribosyltransferase toxin CDTa from Clostridium difficile. J Biol Chem (2009) 1.00
Evidence of in vivo prophage induction during Clostridium difficile infection. Appl Environ Microbiol (2012) 1.00
The second messenger cyclic Di-GMP regulates Clostridium difficile toxin production by controlling expression of sigD. J Bacteriol (2013) 1.00
Impacts of infection with different toxigenic Clostridium difficile strains on faecal microbiota in children. Sci Rep (2014) 1.00
Surface-layer protein A (SlpA) is a major contributor to host-cell adherence of Clostridium difficile. PLoS One (2013) 1.00
The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol (2013) 1.00
Spo0A differentially regulates toxin production in evolutionarily diverse strains of Clostridium difficile. PLoS One (2013) 0.99
Clostridium difficile infection. Nat Rev Dis Prim (2016) 0.99
Variations in virulence and molecular biology among emerging strains of Clostridium difficile. Microbiol Mol Biol Rev (2013) 0.99
Structural determinants of Clostridium difficile toxin A glucosyltransferase activity. J Biol Chem (2012) 0.99
Defining an allosteric circuit in the cysteine protease domain of Clostridium difficile toxins. Nat Struct Mol Biol (2011) 0.99
Transcriptional profiling of Clostridium difficile and Caco-2 cells during infection. J Infect Dis (2010) 0.99
Whole genome sequencing reveals potential spread of Clostridium difficile between humans and farm animals in the Netherlands, 2002 to 2011. Euro Surveill (2014) 0.99
In vivo physiological and transcriptional profiling reveals host responses to Clostridium difficile toxin A and toxin B. Infect Immun (2013) 0.98
Roles of cysteine proteases Cwp84 and Cwp13 in biogenesis of the cell wall of Clostridium difficile. J Bacteriol (2011) 0.98
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet (2005) 12.54
Clinical practice. Antibiotic-associated diarrhea. N Engl J Med (2002) 7.13
Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature (1995) 6.08
Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology (1978) 5.91
Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis (2007) 4.61
The ClosTron: a universal gene knock-out system for the genus Clostridium. J Microbiol Methods (2007) 4.20
The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol (2007) 4.09
Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med (2001) 2.72
Construction and analysis of chromosomal Clostridium difficile mutants. Mol Microbiol (2006) 2.65
Transferable tetracycline resistance in Clostridium difficile. Antimicrob Agents Chemother (1981) 2.56
Repression of Clostridium difficile toxin gene expression by CodY. Mol Microbiol (2007) 2.28
Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol (2008) 2.25
Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun (1987) 2.06
Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol (2007) 2.05
Large clostridial cytotoxins. Rev Physiol Biochem Pharmacol (2004) 2.00
Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol Gen Genet (1992) 2.00
Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis (2006) 1.85
Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol (2007) 1.73
Environmental response and autoregulation of Clostridium difficile TxeR, a sigma factor for toxin gene expression. J Bacteriol (2002) 1.53
Infection of hamsters with epidemiologically important strains of Clostridium difficile. J Infect Dis (2001) 1.52
Large clostridial cytotoxins: cellular biology of Rho/Ras-glucosylating toxins. Biochim Biophys Acta (2004) 1.32
Cholesterol-dependent pore formation of Clostridium difficile toxin A. J Biol Chem (2006) 1.32
Sensitivity in culture of epithelial cells from rhesus monkey kidney and human colon carcinoma to toxins A and B from Clostridium difficile. Toxicon (1992) 1.31
Expression of recombinant Clostridium difficile toxin A using the Bacillus megaterium system. Biochem Biophys Res Commun (2003) 1.21
Translocation of Clostridium difficile toxin B across polarized Caco-2 cell monolayers is enhanced by toxin A. Can J Infect Dis (2004) 1.16
One-step cloning and expression of Clostridium difficile toxin B gene (tcdB). Mol Cell Probes (2002) 0.92
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol (2010) 17.99
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63
Burden of Clostridium difficile infection in the United States. N Engl J Med (2015) 8.17
Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol (2009) 7.89
Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med (2010) 7.37
The ClosTron: a universal gene knock-out system for the genus Clostridium. J Microbiol Methods (2007) 4.20
Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol (2009) 3.66
A mouse model of Clostridium difficile-associated disease. Gastroenterology (2008) 3.65
Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis (2008) 3.32
Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis (2010) 3.31
Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology (2009) 3.29
Using targeted risk factor reduction to prevent falls in older in-patients: a randomised controlled trial. Age Ageing (2004) 3.27
Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis (2007) 3.15
Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 3.13
Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect (2007) 2.84
Skewed genomic variability in strains of the toxigenic bacterial pathogen, Clostridium perfringens. Genome Res (2006) 2.84
Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med (2013) 2.78
An outbreak of eosinophilic meningitis caused by Angiostrongylus cantonensis in travelers returning from the Caribbean. N Engl J Med (2002) 2.76
Genome reduction in Leptospira borgpetersenii reflects limited transmission potential. Proc Natl Acad Sci U S A (2006) 2.71
Construction and analysis of chromosomal Clostridium difficile mutants. Mol Microbiol (2006) 2.65
Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in Hospitals. J Clin Microbiol (2006) 2.52
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother (2007) 2.43
Genome sequence of the saprophyte Leptospira biflexa provides insights into the evolution of Leptospira and the pathogenesis of leptospirosis. PLoS One (2008) 2.35
A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.32
Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol (2010) 2.32
Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.30
Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol (2010) 2.29
NetB, a new toxin that is associated with avian necrotic enteritis caused by Clostridium perfringens. PLoS Pathog (2008) 2.23
Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.22
Construction of an alpha toxin gene knockout mutant of Clostridium perfringens type A by use of a mobile group II intron. Appl Environ Microbiol (2005) 2.01
Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis (2006) 1.99
Toxinotype V Clostridium difficile in humans and food animals. Emerg Infect Dis (2008) 1.98
Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis (2004) 1.98
A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis (2004) 1.96
Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis (2012) 1.96
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85
Strategies to prevent clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.84
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother (2008) 1.84
Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.81
Beta toxin is essential for the intestinal virulence of Clostridium perfringens type C disease isolate CN3685 in a rabbit ileal loop model. Mol Microbiol (2008) 1.78
Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis (2002) 1.68
Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.66
Comparison of strain typing results for Clostridium difficile isolates from North America. J Clin Microbiol (2011) 1.65
Alpha-toxin of Clostridium perfringens is not an essential virulence factor in necrotic enteritis in chickens. Infect Immun (2006) 1.62
Staphylococcus aureus and Clostridium difficile cause distinct pseudomembranous intestinal diseases. Clin Infect Dis (2004) 1.58
Environmental response and autoregulation of Clostridium difficile TxeR, a sigma factor for toxin gene expression. J Bacteriol (2002) 1.53
Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol (2004) 1.52
Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hands. Infect Control Hosp Epidemiol (2010) 1.51
Revised nomenclature for transposable genetic elements. Plasmid (2008) 1.50
Epsilon-toxin is required for most Clostridium perfringens type D vegetative culture supernatants to cause lethality in the mouse intravenous injection model. Infect Immun (2005) 1.49
Dissecting the contributions of Clostridium perfringens type C toxins to lethality in the mouse intravenous injection model. Infect Immun (2006) 1.49
Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. Anaerobe (2009) 1.47
Workshop on research priorities for management and treatment of angiostrongyliasis(1). Emerg Infect Dis (2012) 1.43
Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol (2003) 1.43
Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis (2012) 1.42
Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. Clin Infect Dis (2010) 1.41
Rethinking our understanding of the pathogenesis of necrotic enteritis in chickens. Trends Microbiol (2008) 1.39
Molecular epidemiology of Clostridium difficile over the course of 10 years in a tertiary care hospital. Clin Infect Dis (2009) 1.39
Functional identification of conjugation and replication regions of the tetracycline resistance plasmid pCW3 from Clostridium perfringens. J Bacteriol (2006) 1.39
Study of feline injection site sarcomas. Vet Rec (2006) 1.38
The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives. Gut Microbes (2010) 1.37
Self-produced exopolysaccharide is a signal that stimulates biofilm formation in Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (2012) 1.36
Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother (2011) 1.33